Table 2.
PD-L1 Detection Methods From the Included Studies
| Study | Detection Method | Primary Antibody |
Cutoff Value, % | ||||
|---|---|---|---|---|---|---|---|
| Antibody Source | Antibody Type | Antibody Clone | Antibody Dilution | Antibody Company | |||
| Retrospective studies | |||||||
| Cantini et al., 202012 | IHC | NR | NR | 22C3 or SP263 | NR | NR | ≥1 |
| Cedrés et al., 20155 | IHC | Rabbit | MAB | E1L3N | 1:1200 | Cell Signaling Technology, Danvers, MA | ≥1 |
| Combaz-Lair et al., 20168 | IHC | Rabbit | MAB | E1L3N | 1:100 | Cell Signaling Technology, Danvers, MA | ≥1% |
| Rabbit | NR | SP142 | 1:60 | Spring Bioscience | ≥1 | ||
| Chapel et al., 201913 | IHC | NR | NR | 22C3 | NR | Dako pharmDx, Carpinteria, CA | ≥1 |
| 28-8 | NR | NR | ≥1 | ||||
| De Perrot et al., 202014 | IHC | NR | NR | 28-8 | 1:200 | Abcam Inc., Toronto, Ontario, Canada | ≥1% |
| Ferdinandus et al., 202015 | IHC | NR | NR | 28-8 | NR | Abcam | NR |
| Forest et al., 201816 | IHC | NR | NR | 22C3 | 1:40 | Agilent, Santa Clara, CA | ≥1 |
| Inaguma et al., 202019 | IHC | Mouse | NR | EPR4877 | 1:200 | Abcam | NR |
| Inaguma et al., 201817 | IHC | Rabbit | MAB | E13LN | 1:200 | Cell Signaling Technology, Danvers, MA | ≥5 |
| Jiang et al., 202018 | IHC | NR | NR | NR | NR | NR | ≥1 |
| Kao et al., 201720 | IHC | Rabbit | MAB | E13LN | 1:75 | Cell Signaling Technology, Danvers, MA | ≥5% |
| Mansfield et al., 201421 | IHC | Mouse | MAB | 5H1-A3 | 1:300 | NR | ≥5 |
| Metaxas et al., 201822 | IHC | Rabbit | MAB | E1L3N | NR | Cell Signaling Technology, Danvers, MA | ≥5 |
| Muller et al., 202023 | IHC | Rabbit | MAB | E1L3N | 1:100 | Cell Signaling Technology, Danvers, MA | ≥1 |
| Nguyen et al., 201824 | IHC | Rabbit | MAB | SP263 | NR | Ventana | ≥1 |
| Sobhani et al., 201925 | IHC | NR | MAB | 22C3 | 1:50 | Agilent Dako | NR |
| Tallón de Lara et al., 201826 | IHC | NR | NR | E13LN | 1:1000 | Cell Signaling Technology, Danvers, MA | ≥1 |
| Thapa et al., 201727 | IHC | Rabbit | MAB | E13LN | NR | Cell Signaling Technology, Danvers, MA | ≥1 |
| Watanabe et al., 201828 | IHC | NR | NR | SP142 | NR | Ventana Medical Systems, Tucson, AZ | ≥1 |
| Prospective studies | |||||||
| Brosseau et al., 201929 | IHC | NR | NR | E1L3N | 1:400 | CST or Ozyme | ≥1 |
| Cedres et al. 201630 | IHC | Rabbit | MAB | E1L3N | 1:1200 | Cell Signaling Technology, Danvers, MA | ≥1 |
| Disselhorst et al., 201931 | IHC | NR | NR | 22C3 | NR | Agilent pharmDx, Santa Clara, CA | ≥1 |
| Quispel-Janssen et al., 201832 | IHC | NR | MAB | 28-8 | NR | Agilent Dako, Santa Clara, CA | ≥1 |
| Cross-sectional studies | |||||||
| Salaroglio et al., 201933 | IHC | Mouse | NR | 29E.2A3 | 1:100 | BioLegend, San Diego, CA | NR |
| Nonrandomized trials | |||||||
| Alley et al., 201734 | IHC | NR | NR | 22C3 | NR | Dako pharmDx, Carpinteria, CA | ≥1 |
| Okada et al., 201936 | IHC | NR | NR | 28-8 | NR | Dako | ≥1 |
| Randomized trials | |||||||
| Popat et al., 202037 | IHC | NR | NR | SP263 | NR | NR | ≥1 |
| E1L3N | NR | NR | ≥1 | ||||
| Scherpereel et al., 201938 | IHC | NR | MAB | 28-8 | NR | Dako pharmDx, Carpinteria, CA | ≥1 |
| MAB | SP263 | NR | NR | ≥1 | |||
IHC, immunohistochemistry; MAB, monoclonal antibody; NR, not reported.